Retinoid hepatitis.
A 65-year-old woman treated with etretinate for pityriasis rubra pilaris developed chronic active hepatitis. The elevated transaminases were noted 2 months after initiation of therapy and peaked 2 months after discontinuation of etretinate. The spectrum of liver toxicity induced by etretinate is reviewed. We suggest that reported cases of retinoid-induced liver disease can be divided into four distinct categories: nonspecific reactive hepatitis, acute hepatitis, chronic active hepatitis, and severe fibrosis or cirrhosis.
Sanchez
M R
MR
Department of Dermatology, New York University Medical Center, NY 10016.
Ross
B
B
Rotterdam
H
H
Salik
J
J
Brodie
R
R
Freedberg
I M
IM
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D056487:Chemical and Drug Induced Liver Injury, Chronic; D005050:Etretinate / Q000009:adverse effects*; D005260:Female; D006521:Hepatitis, Chronic / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D010916:Pityriasis Rubra Pilaris / Q000188:drug therapy
D005050:Etretinate